Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

@inproceedings{Kaufman2015PhaseIO,
  title={Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane},
  author={Peter A. Kaufman and Ahmad Awada and Chris Twelves and Louise Yelle and Edith A Perez and Galina Velikova and Martin Sebastian Olivo and Yi He and Corina E. Dutcus and Javier Bascu{\~n}{\'a}n Cort{\'e}s},
  booktitle={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015}
}
PURPOSE This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC). PATIENTS AND METHODS Women with MBC who had received prior anthracycline- and taxane-based therapy were randomly assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy for advanced/metastatic disease. Stratification factors were human epidermal growth factor… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 110 CITATIONS, ESTIMATED 54% COVERAGE

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.

  • Journal of breast cancer
  • 2016
VIEW 16 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
VIEW 13 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

  • Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 23 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL